Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group
暂无分享,去创建一个
E. V. Van Allen | G. Ha | B. Crompton | K. Stegmaier | P. Leavey | A. Thorner | S. Lessnick | W. London | K. Janeway | R. Gorlick | M. Krailo | D. Barkauskas | L. Mascarenhas | S. DuBois | D. Shulman | K. Klega | Alma Imamovic-Tuco | David Hall | Anwesha Nag | Andrea Clapp | K. Vo
[1] M. Meyerson,et al. Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. , 2018, JCO precision oncology.
[2] R. Dubin,et al. Detection of circulating tumor DNA in patients with osteosarcoma , 2018, Oncotarget.
[3] Nikhil Wagle,et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors , 2017, Nature Communications.
[4] V. Plagnol,et al. Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection , 2017, Cancer medicine.
[5] A. Viale,et al. Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas. , 2017, JCO precision oncology.
[6] James D. Brenton,et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.
[7] K. S. Hall,et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial , 2016, The Lancet. Oncology.
[8] J. Wolinsky,et al. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA , 2016, Cancer.
[9] U. Dirksen,et al. Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma , 2016, Clinical Cancer Research.
[10] K. Matthay,et al. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group , 2016, Clinical Cancer Research.
[11] M. Segal,et al. Identification of Discrete Prognostic Groups in Ewing Sarcoma , 2016, Pediatric blood & cancer.
[12] Li Ding,et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.
[13] L. Donehower,et al. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma , 2015, Cancer medicine.
[14] W. Hahn,et al. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers , 2014, Nucleic acids research.
[15] Li Ding,et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.
[16] M. Gong,et al. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma , 2014, Tumor Biology.
[17] A. McKenna,et al. The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.
[18] Jun S. Wei,et al. The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.
[19] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[20] J. Healey,et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Baruchel,et al. Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma , 2012, Pediatric blood & cancer.
[22] H. Toledano,et al. Excellent Prognosis in a Subset of Patients with Ewing Sarcoma Identified at Diagnosis by CD56 Using Flow Cytometry , 2011, Clinical Cancer Research.
[23] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[24] M. Stratton,et al. Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors , 2010, Genes, chromosomes & cancer.
[25] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[26] M. Ychou,et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts , 2010, Nucleic acids research.
[27] K. Matthay,et al. Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow , 2010, Pediatric blood & cancer.
[28] Piero Picci,et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.
[29] S. Donaldson,et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.
[30] W. Winkelmann,et al. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas , 2002, International journal of cancer.
[31] Bruno Landi,et al. Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis , 2002, International journal of cancer.
[32] T. Yamashita,et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma , 2002, British Journal of Cancer.
[33] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. Craft,et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Shuster,et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.
[36] Claude-Alain H. Roten,et al. Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..
[37] O. Delattre,et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.